NEXT DAY DISCLOSURE RETURN

VOLUNTARY ANNOUNCEMENT - DATA FROM TWO CLINICAL STUDIES OF M701 “CD3/EpCAM BISPECIFIC ANTIBODY” PRESENTED AT 2026 ASCO

VOLUNTARY ANNOUNCEMENT - ZONGERTINIB, A HER2 TYROSINE KINASE INHIBITOR, APPROVED FOR FIRST-LINE TREATMENT OF HER2-MUTANT NON-SMALL CELL LUNG CANCER

NEXT DAY DISCLOSURE RETURN

NEXT DAY DISCLOSURE RETURN

NEXT DAY DISCLOSURE RETURN

NEXT DAY DISCLOSURE RETURN

NEXT DAY DISCLOSURE RETURN